It's known that people with high blood pressure have increased levels of the enzyme lysyl oxidase (LOX), but it has not been clear if LOX actually contributes to heart disease. Now, a new research report appearing online in The FASEB Journal helps answer this question by showing that LOX does negatively affect heart function in mice.
"Our data suggest that drugs preventing the increase of LOX in the heart will be interesting for the treatment of heart disease," said Cristina Rodriguez, researcher at the Catalan Institute of Cardiovascular Diseases, Barcelona, Spain. "LOX is also increased in other diseases, including Alzheimer's disease and certain types of cancers. Eventually, we hope to develop treatments to benefit patients with increased LOX across all of these diseases."
To test the effects of increased amounts LOX in the heart, Rodríguez and colleagues used four groups of mice: 1) normal mice, 2) normal mice treated with a drug that enhances blood pressure and causes heart disease (angiotensin II), 3) mice with high levels of human LOX in the heart (named "TgLOX mice"), and 4) TgLOX mice treated with angiotensin II. The researchers observed that the TgLOX mice with angiotensin II experienced a more severe heart disease than that triggered in normal mice with angiotensin II.
"Leads like this richly catalyze the field," said Thoru Pederson, Ph.D., Editor-in-Chief of The FASEB Journal. "Every new door in heart disease is a portal worth entering."
Submit to The FASEB Journal by visiting http://fasebj.msubmit.net, and receive monthly highlights by signing up at http://www.faseb.org/fjupdate.aspx. The FASEB Journal is published by the Federation of the American Societies for Experimental Biology (FASEB). It is among the world's most cited biology journals according to the Institute for Scientific Information and has been recognized by the Special Libraries Association as one of the top 100 most influential biomedical journals of the past century.
FASEB is composed of 30 societies with more than 125,000 members, making it the largest coalition of biomedical research associations in the United States. Our mission is to advance health and welfare by promoting progress and education in biological and biomedical sciences through service to our member societies and collaborative advocacy.
Details: María Galán, Saray Varona, Anna Guadall, Mar Orriols, Miquel Navas, Silvia Aguiló, Alicia de Diego, María A. Navarro, David García-Dorado, Antonio Rodríguez-Sinovas, José Martínez-González, and Cristina Rodriguez. Lysyl oxidase overexpression accelerates cardiac remodeling and aggravates angiotensin II-induced hypertrophy. FASEB J. doi: 10.1096/fj.201601157RR ; http://www.fasebj.org/content/early/2017/05/18/fj.201601157RR.abstract
The FASEB Journal